# LUNAR (NCT05496959)

> 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05496959
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Jonsson Comprehensive Cancer Center
- Conditions: Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma; Recurrent Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
- Interventions: Lutetium Lu-177 PNT2002; Quality-of-Life Assessment; Stereotactic Body Radiation Therapy
- Enrollment: 93
- Primary outcome: Prostate-specific membrane antigen positron emission tomography/computerized tomography (PSMA PET/CT)-based progression-free survival (PFS)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lunar-nct05496959